trans-pacific partnership

Printer-friendly version

For smaller countries, access to the U.S. market is a major prize.

Printer-friendly version

Canada’s lagging intellectual property (IP) protections for pharmaceutical innovators are a key issue to be settled in the Comprehensive Economic and Trade Agreement (CETA) negotiations with the European Union. They may also play a role in upcoming negotiations for the multi-country Trans-Pacific Partnership (TPP).